Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
NCT06103734 · Pfizer · PHASE3 · withdrawn · last registry update 2026-01-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Strategic decision to cancel the study based on adjusted clinical development plan.” | – | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RAMP1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-22Results posted on the registry: Pfizer, Zavegepant + Placebo (NCT05989048)
- 2026-04-29Also stopped (terminated): Icahn School of Medicine at Mount Sinai, Rimegepant + Zavegepant (NCT06985342)
- 2026-04-17Also stopped (withdrawn): Esbjerg Hospital - University Hospital of Southern Denmark, Pramlintide Acetate 1 MG/ML + Semaglutide Pen Injector (NCT06619015)
- 2026-03-05Results posted on the registry: Oregon Health and Science University, a drug against RAMP1 (NCT06422325)
- 2026-01-29Results posted on the registry: Pfizer, Zavegepant 10 mg IN (NCT05948085)
- 2025-03-27Results posted on the registry: Pfizer, BHV-3500 (zavegepant) + Placebo (NCT04804033)
- 2025-03-27Also stopped (terminated): Pfizer, BHV-3500 (zavegepant) + Placebo (NCT04804033)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision